论文部分内容阅读
通过查阅相关文献和网站,分析我国抗菌药物研发存在的问题及原因,并有针对性地提出建议。我国抗菌药物面临高耐药率和研发储备不足的严峻形势,抗菌药物研发存在的问题有:研发投入低,避开研发技术难关、扎堆仿制及上市后收益低等。我国应制定使创新型抗菌药物上市后获得高收益的激励措施,让企业积极克服高技术、高投入、高风险和长周期的难题。高收益需高销售量、高价格和市场回报周期长作为支撑。因此可分别采取提高政府采购承诺、延长市场独占期提高销量;参考同类药品国际价格制定高价格;加快审批、合理使用延长回报周期等措施。
Through consulting the relevant literature and websites, this paper analyzes the problems and causes of antimicrobial drug research and development in China and puts forward some suggestions. Anti-bacterial drugs in China are facing a severe situation of high drug resistance rate and insufficient R & D reserve. The problems in R & D of anti-bacterial drugs are as follows: R & D investment is low, technology research and development is avoided, China should formulate incentives for high-yielding innovative antibacterial drugs after it goes on the market and enable enterprises to actively overcome the challenges of high-tech, high input, high-risk and long-term. High yield to be high sales, high prices and long market returns as a support. Therefore, measures such as improving government procurement promises, extending market monopoly period and increasing sales volume can be taken respectively. Reference is made to international prices of similar drugs to set high prices. Measures such as expediting examination and approval and rationalizing the use of extended payback periods are also available.